SRTA Stock Analysis: Buy, Sell, or Hold?
SRTA - Strata Critical Medical, Inc. Class A Common Stock
$5.51
-0.06 (-1.08%)
▼
5d:
-5.65%
30d:
-10.11%
90d:
+27.99%
HOLD
LOW Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Get Alerted When SRTA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SRTA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: SRTA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: SRTA is currently trading at $5.51, which is considered slightly low relative to its 30-day fair value range of $5.49 to $6.18. From a valuation perspective, the stock is trading at a discount (Forward PE: -551.0) compared to its historical average (61.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SRTA is showing support break momentum. The price is currently testing key support at $5.40. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.25 (+67.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SRTA is showing support break momentum. The price is currently testing key support at $5.40. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.25 (+67.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$5.49 -
$6.18
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 67.9% below Wall St target ($9.25)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Recommendation downgraded due to -5.7% 5-day decline
Trading Range Analysis
30-Day Trading Range
$5.49 -
$6.18
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$5.40
Resistance Level
$6.50
Current Trend
Support Break
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-551.00
Wall Street Target
$9.25
(+67.9%)
Revenue Growth (YoY)
87.4%
Profit Margin
20.6%
PE vs Historical
-551.0 vs 61.6
CHEAP
Share & Embed Analysis
Last updated: June 24, 2026 6:02 PM ET
Data refreshes hourly during market hours. Next update: 7:02 PM
Data refreshes hourly during market hours. Next update: 7:02 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SRTA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Care Facilities Stocks
Top-rated stocks in Medical Care Facilities by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
THC
Tenet Healthcare Corpora… |
STRONG BUY
22 analysts |
$244 | 57 HOLD |
|
HCA
HCA Healthcare, Inc. |
BUY
25 analysts |
$504 | 58 HOLD |
|
EHC
Encompass Health Corp |
STRONG BUY
12 analysts |
$141 | 55 HOLD |
|
CMPS
Compass Pathways Plc |
STRONG BUY
11 analysts |
$22 | 54 HOLD |
|
ADUS
Addus HomeCare Corporati… |
STRONG BUY
11 analysts |
$133 | 58 HOLD |